 impella sale fell slightli short street
expect ou result in-lin along mani investor thought
 result would come light continu trend flattish revenu last
coupl quarter though shock procedur grew protect pci growth
remain rel modest ou result though forecast
meaning sequenti ramp constant currenc growth strong
increment oper margin improv light salesforc
spend also encourag
overal walk away differ view challeng
turn form basi neutral stanc though think begin
address educ help vascular complic fear creat
deeper bench dotor help decid move low-risk tavr
area new product easier y/i comp come sens
fallout rp letter dissip well
share mid-day trade surpris us thought
slight miss would keep thing range-bound seem investor thought
guidanc would lower maintain even low end target
enough buoy share
believ thing get better time base above-ment
effort reason share fallen today would found attract
share trade ntm sale estim still peer group
fast-grow med-tech name reason given compani margin even
seem multipl would fine fair share pull back would look close
like new effort didnt expect run today in-lin result maintain
pipelin updat track besid momentum commerci launch
smartassist updat ecp also promis today management
announc limit market releas disclos patient
treat octob besid thinner profil higher pump flow rate
appeal heart surgeon meanwhil expand sheath
target limit roll-out end ecp
commerci sheath management project fim trial
commenc end fiscal year agre introduct
smaller catheth address challeng access closur
tweak revenu estim trim revenu
forecast miss overli aggress ou estim forecast
sale impli growth
valuat maintain neutral rate risk page
idc btig estim compani document
million except per share amount
rate neutral believ stori mani posit robust cash high margin potenti
indic expans under-penetrated market high barrier entri howev recent miss difficult
understand suggest address market may slower previous estim btig provid
price target neutral-r stock
stabl procedur growth price
expans current tam
cut reimburs
key product impella
enabl doctor use
cathet deliv tini heart
pump patient femor
arteri heart impella
move oxygen blood
left ventricl heart
bodi organ reliev
diseas heart help stabil
patient increas blood flow
compani report world-wide impella revenu lower forecast impella revenu
grow y/i year compani open new site far site open last year
impella growth meanwhil ou impella revenu improv constant currenc basi
support higher patient util japan germani adopt switzerland austria itali
revenu japan improv y/i spur patient util new site japan abiom open
site hospit vs hospit approv govern manag expect open fewer
site close pa studi priorit broader cp launch requir train
gross margin stronger forecast gross margin fell reflect pressur
smartassist launch geograph sale mix despit improv plant product sg spend better
model reflect invest commerci team train overal ebit margin higher
model mainli lower oper expens better compar estim non-gaap ep
exclud one-tim invest loss tax benefit turn surpass
flow miss trim ou estim conserv forecast japan
model consolid sale repres growth y/i maintain adj ebit
margin assum higher sg spend back half support commerci effort beyond
keep revenu estim larg unchang
actualsbtig estimate varianceestim impella sale trial impella sale revenu net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani non- ep add unreal loss compani investmentin rate deduct etb varianc
rate neutral believ stori mani posit robust cash high margin potenti
indic expans under-penetrated market high barrier entri howev recent miss difficult
understand suggest address market may grow slowli previous estim btig
provid price target neutral-r stock risk includ rebound protect pci volum reimburs cut
slippag product timelin chang procedur patent litig unsuccess data competit fda
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom ep btig estim compani adjust ep adjust gains/loss invest shockwav rate excess tax benefit changentm inc ingnnot technologiesirtcbuy factset data btig estimatesintra-day price ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
